[Form 4] Cytek Biosciences, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cytek Biosciences president and CEO Wenbin Jiang reported equity award activity involving restricted stock units and common shares. On February 18, 2026, 4,514 restricted stock units were converted into 4,514 shares of common stock at a price of 0.00 per share.
The Form 4 shows that 1,339 of these common shares, valued at 4.20 per share, were withheld and surrendered to Cytek Biosciences to cover tax withholding obligations tied to the vesting of this RSU award. After these transactions, Jiang directly held 5,359,827 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
4,514 shares exercised/converted
Mixed
3 txns
Insider
Jiang Wenbin
Role
PRESIDENT AND CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 4,514 | $0.00 | -- |
| Exercise | Common Stock | 4,514 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,339 | $4.20 | $6K |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct);
Common Stock — 5,361,166 shares (Direct)
Footnotes (1)
- Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Represents the number of shares withheld by and surrendered to the Issuer on February 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.